表紙
市場調査レポート

腫瘍学バイオシミラーの世界市場:2016〜2020年

Global Oncology Biosimilars Market 2016-2020

発行 TechNavio (Infiniti Research Ltd.) 商品コード 319672
出版日 ページ情報 英文 109 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
腫瘍学バイオシミラーの世界市場:2016〜2020年 Global Oncology Biosimilars Market 2016-2020
出版日: 2016年02月17日 ページ情報: 英文 109 Pages
概要

癌は高い治療費などにより医療制度の大きな負担となっています。多くの癌治療薬の特許が失効することで、バイオシミラーが市場に参入してきました。バイオシミラーは、モノクローナル抗体、タンパク質、ホルモン、核酸、コロニー刺激因子、インターロイキン、酵素などの生物学的要素によって合成されます。世界の腫瘍学バイオシミラー市場は、2016〜2020年にかけCAGR31.76%で拡大すると予測されています。

当レポートでは、世界の腫瘍学バイオシミラー市場の現状と今後の成長見通し、地域別動向とともに、市場の動向と課題、主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの範囲

第3章 市場調査方法

第4章 イントロダクション

第5章 癌の概要

  • 疫学
  • 癌の経済的負担

第6章 バイオシミラー業界

  • バイオシミラーとジェネリック小分子との比較
  • 生物製剤とバイオシミラーに影響を及ぼす因子
  • バイオシミラー:ビジネスと価格戦略
  • バイオシミラー摂取に影響を及ぼす因子
  • バイオシミラーの機械
  • バイオシミラーの成長
  • 様々な地域での先発品とバイオシミラーの市場普及度
  • 世界の腫瘍学バイオシミラー市場における現在および将来動向
  • 新規参入者にとっての課題

第7章 世界の医薬品市場

  • 市場規模予測
  • 世界のバイオシミラー市場

第8章 市況

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第9章 エンドユーザー別市場セグメンテーション

  • 病院
  • 小売薬局

第10章 用途別市場セグメンテーション

  • 癌治療薬
  • 補足的ケア薬剤

第11章 地域別セグメンテーション

  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域

第12章 主要地域

  • 米国
  • 欧州
  • 日本
  • インド
  • 中国

第13章 市場促進因子

第14章 促進因子の影響

第15章 市場の課題

第16章 促進因子および課題の影響

第17章 市場動向

第18章 ベンダー環境

  • 競合シナリオ
  • Biocon
  • Celltrion
  • Dr. Reddy's Laboratories
  • F Hoffmann-La Roche
  • Hospira
  • Mylan
  • Sandoz
  • その他の注目すべきベンダー

第19章 付録

第20章 Technavioについて

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR8749

About Oncology Biosimilars

Cancer represents a huge burden on healthcare systems worldwide due to the high cost of treatment therapeutics. The patent expiry of many cancer therapeutics enables the entry of biosimilars into the market. Biosimilars are being incorporated into oncology treatment practices in the supportive care setting. Biosimilars are synthesized with the use of biologic components such as monoclonal antibodies, proteins, hormones, nucleic acids, colony stimulating factors, interleukins, and enzymes.

Technavio's analysts forecast the global oncology biosimilars market to grow at a CAGR of 31.76% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global oncology biosimilars market for the period 2016-2020. To calculate the market size, the report considers revenue generated from the sales of biosimilars used to treat cancer.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Oncology Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Biocon
  • Celltrion
  • Dr. Reddy's Laboratories
  • F. Hoffmann-La Roche
  • Hospira
  • Mylan
  • Sandoz

Other Prominent Vendors

  • AbbVie
  • Allergan
  • Amgen
  • AstraZeneca
  • Baxter
  • Biogen
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Cipla
  • Coherus BioSciences
  • Coherus BioSciences
  • Daiichi Sankyo
  • Emcure Pharmaceuticals
  • GlaxoSmithKline (GSK)
  • Intas Pharmaceuticals
  • Merck
  • Pfizer
  • Sanofi
  • 3SBio
  • Wockhardt

Market driver

  • Rise in number of patent expiries
  • For a full, detailed list, view our report

Market challenge

  • Risks related to failure of drugs in the market
  • For a full, detailed list, view our report

Market trend

  • Emergence of biosimilars
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Overview of cancer

  • Epidemiology
  • Economic burden of cancer

PART 06: Biosimilars industry

  • Comparison between biosimilars and generic small molecules
  • Factors influencing biologics and biosimilars
  • Biosimilars: business and pricing strategy
  • Factors affecting the uptake of biosimilars
  • Biosimilar opportunities
  • Growth of biosimilars 2014- 2020
  • Market penetration of originators and biosimilars in different regions
  • Current and future trends in global oncology biosimilars market
  • Challenges for new entrants

PART 07: Global pharmaceutical market

  • Market size and forecast
  • Global biosimilars market

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by end-user

  • Hospitals
  • Retail pharmacies

PART 10: Market segmentation by application

  • Cancer treatment drugs
  • Supportive care drugs

PART 11: Geographical segmentation

  • Global oncology biosimilar drugs market by geographical segmentation 2015-2020
  • Oncology biosimilars market in EMEA
  • Oncology biosimilars market in APAC
  • Oncology biosimilars market in Americas

PART 12: Key leading regions

  • US
  • Europe
  • Japan
  • India
  • China

PART 13: Market drivers

  • Rise in number of patent expiries
  • Increase in prevalence of cancer
  • Growing aging population
  • Promising drug pipeline
  • Need for cost-effective treatment
  • Favorable government regulations

PART 14: Impact of drivers

PART 15: Market challenges

  • Risks related to failure of drugs in market
  • Multiple manufacturing complexities
  • Reluctance among physicians to prescribe biosimilar products
  • Complicated regulatory process
  • Limited availability of biosimilar products
  • Risk of side effects

PART 16: Impact of drivers and challenges

PART 17: Market trends

  • Emergence of biosimilars
  • Outsourcing of biosimilar manufacturing activities
  • Rising number of strategic collaborations
  • Increase in cancer awareness
  • Rise in R&D

PART 18: Vendor landscape

  • Competitive scenario
  • Biocon
  • Celltrion
  • Dr. Reddy's Laboratories
  • F Hoffmann-La Roche
  • Hospira
  • Mylan
  • Sandoz
  • Other prominent vendors

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global biosimilars and oncology biosimilars market 2015
  • Exhibit 03: Cancer burden in European Union (EU)
  • Exhibit 04: Global incidence of cancer 2015
  • Exhibit 05: Global mortality of cancer type 2015
  • Exhibit 06: Estimated numbers of cancer survivors by age in US 2014
  • Exhibit 07: Definition of biosimilars in different regions
  • Exhibit 08: Comparison between biosimilars and generic small molecules
  • Exhibit 09: Factors influencing biologics and biosimilars
  • Exhibit 10: Impact of biosimilars cost savings on various sectors
  • Exhibit 11: Factors affecting success of biosimilars
  • Exhibit 12: Biosimilars industry: Point-of-view
  • Exhibit 13: Factors affecting the uptake of biosimilars
  • Exhibit 14: Strategic factors for new entrant
  • Exhibit 15: Growth of biosimilars
  • Exhibit 16: Share of biosimilars in recombinant drugs sales in major markets 2014
  • Exhibit 17: Trends in global oncology biosimilars market
  • Exhibit 18: Challenges for new entrants
  • Exhibit 19: Global pharmaceutical market 2015-2020 ($ trillions)
  • Exhibit 20: Global biosimilars market 2015-2020 ($ billions)
  • Exhibit 21: Number of approved biosimilars in regulated and semi-regulated markets
  • Exhibit 22: Global pharmaceutical, biosimilars, and oncology biosimilars market 2015 ($ billions)
  • Exhibit 23: Global oncology biosimilars market 2015-2020 ($ billions)
  • Exhibit 24: Global oncology biosimilars market overview
  • Exhibit 25: Five forces analysis
  • Exhibit 26: Oncology biosimilars market segmentation by end-user 2014
  • Exhibit 27: Global oncology biosimilars segmentation by application
  • Exhibit 28: Oncology biosimilars by application
  • Exhibit 29: Global oncology biosimilars market by geographical segmentation 2015
  • Exhibit 30: Global oncology biosimilars market revenue by geography 2015-2020 ($ billions)
  • Exhibit 31: Oncology biosimilars market in EMEA 2015-2020 ($ billions)
  • Exhibit 32: Oncology biosimilars market in APAC 2015-2020 ($ billions)
  • Exhibit 33: Oncology biosimilars market in Americas 2015-2020 ($ billions)
  • Exhibit 34: Global oncology biosimilars market: YoY revenue and growth based on geography 2015-2020 ($ billions)
  • Exhibit 35: Key leading regions
  • Exhibit 36: Pharmaceutical R&D expenditure in US 2010-2015 ($ billions)
  • Exhibit 37: Approvals of biologicals versus biosimilars via PHSA
  • Exhibit 38: Approval process for biosimilars in US
  • Exhibit 39: Benefits of biosimilars to US healthcare system
  • Exhibit 40: Role of stake holders
  • Exhibit 41: SWOT analysis
  • Exhibit 42: Oncology biosimilars approved by EMA in Europe
  • Exhibit 43: Guidelines for biosimilars in EU
  • Exhibit 44: Time line of biosimilars in Europe
  • Exhibit 45: Key stake holders
  • Exhibit 46: Key drivers and restraints
  • Exhibit 47: Biosimilar industry challenges in Europe
  • Exhibit 48: SWOT analysis
  • Exhibit 49: Biosimilars approved by PMDA in Japan
  • Exhibit 50: Review process for biosimilars in Japan
  • Exhibit 51: Drivers and challenges in oncology biosimilars market in Japan
  • Exhibit 52: SWOT analysis
  • Exhibit 53: Biosimilars approved in India
  • Exhibit 54: Timeline for development of biosimilars in India
  • Exhibit 55: Challenges and strategies
  • Exhibit 56: Major domestic and international vendors operating in India
  • Exhibit 57: Drivers and challenges
  • Exhibit 58: SWOT analysis
  • Exhibit 59: Top domestic and international vendors operating in China
  • Exhibit 60: Drivers and challenges
  • Exhibit 61: SWOT analysis
  • Exhibit 62: Patent expiries of oncology biologics in US and EU 2020
  • Exhibit 63: Global incidence of cancer 2015 and 2020
  • Exhibit 64: Impact of drivers
  • Exhibit 65: Impact of drivers and challenges
  • Exhibit 66: Global competitive landscape 2015
  • Exhibit 67: Biocon: Key takeaways
  • Exhibit 68: Celltrion: Key takeaways
  • Exhibit 69: Dr. Reddy's Laboratories: Key takeaways
  • Exhibit 70: F. Hoffmann-La: Key takeaways
  • Exhibit 71: Hospira: Key takeaways
  • Exhibit 72: Mylan: Key takeaways
  • Exhibit 73: Sandoz: Key takeaways
Back to Top